共 8 条
[1]
The first clinical trial using triple therapy Combivir plus Indinavir in Chinese Individuals with HIV Infection. Cao Y,Zhang FJ,Mei S,et al. Chinese Journal of Internal Medicine . 2002
[2]
A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HV-1 infection. Markowitz M,Saag M,Powderly WG,et al. The New England Journal of Medicine . 1995
[3]
Virological and immunological characterization of long-term survivors with infection of HIV-1. Cao Y,Qin LM,Zhang LQ,et al. New England Journal of Homeopathy . 1995
[4]
Clinical update on 24 weeks Combination therapy with once a day Efavirenz and three times a dayIndinavir in HIV-1 infected patients in China. Cao Y,Zhang FJ,Zhou ZQ,et al. . 2001
[5]
Zalcitabine compared with zidovudine in patients with advanced HIV-1 infection who received previous zidovudine therapy. Fischl MA,Olson RM,Follansbee SE,et al. Annals of Internal Medicine . 1993
[6]
The alpha trial: European/Australian randomized double-blind trial of two doses of didanosine in zidovudine-intolerant patients with symptomatic HV disease. Alpha International Coordinating committee. AIDS . 1996
[7]
Virologic and immunologic benefits of initial combination therapy with zidovudine and zalcitabine or didanosine compared with zidovudine monotherapy. Schooley RT,Ramirez-Ronda C,Lange JM,et al. The Journal of Infectious Diseases . 1996
[8]
Rapid restoration of CD4 T cell subsets in subjects receiving antiretroviral therapy during primary HIV-1 infection. Kaufmann GR,Zaunders JJ,Cunningham P,et al. AIDS . 2000